Sims EAH, Danforth E, Horton ES. Endocrine and metabolic effects of experimental obesity in man. Recent progress in hormone research. Volume 29. Academic Press, Inc.; 1973. pp. 457–96. https://doi.org/10.1016/B978-0-12-571129-6.50016-6.

Lois K, Kumar S. Obesity and diabetes. Endocrinol Y Nutr. 2009;56:38–42. https://doi.org/10.1016/S1575-0922[09]73516-8.

Article  Google Scholar 

Kumar N, Puri N, Marotta F, Dhewa T, Calabrò S, Puniya M et al. Diabesity: an epidemic with its causes, prevention and control with special focus on dietary regime. Funct Foods Heal Dis. 2017;7(1):1–16.

Verma S, Hussain ME. Obesity and diabetes: an update. Diabetes Metab Syndr Clin Res Rev. 2017;111:73–9. https://doi.org/10.1016/j.dsx.2016.06.017.

Article  Google Scholar 

Pereira SS, Alvarez-Leite JI. Low-Grade inflammation, obesity, and diabetes. Curr Obes Rep. 2014;34:422–31.

Article  Google Scholar 

Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world - A growing challenge. N Engl J Med. 2007;3563:213–5.

Article  Google Scholar 

Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;4146865:782–7.

Article  Google Scholar 

Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007;4457130:881–5.

Article  Google Scholar 

Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;3689548:1681–8.

Article  Google Scholar 

Wannamethee SG, Shaper AG, Walker M. Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Community Health. 2005;592:134–9.

Article  Google Scholar 

Campbell LV. How many cases of type 2 diabetes mellitus are due to being overweight in middle age? Evidence from the midspan prospective cohort studies using mention of diabetes mellitus on hospital discharge or death records [1]. Diabet Med. 2007;X(10):1172–3.

Montague C, O’Rahilly S. Causes and consequences of visceral adiposity. Diabetes Journals. 2000;49(6):883–8. http://diabetes.diabetesjournals.org/content/diabetes/49/6/883.full.pdf

Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance. Diabet Med. 2005;226:674–82.

Article  Google Scholar 

Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009;10636:15430–5.

Article  Google Scholar 

Shepherd PR, Kahn BB. Glucose transporters and insulin action. N Engl J Med. 1999;3414:248–57.

Article  Google Scholar 

Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a National cohort of US adults. Am J Epidemiol. 1997;1463:214–22.

Article  Google Scholar 

Scha. Lipotoxicity: when tissues overeat. Curr Opin Lipidol. 2003;14(3):281–7.

Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Sci [80- ]. 2005;3075708:384–7.

Article  Google Scholar 

Furukawa S, Matsuda M, Furukawa S, Fujita T, Shimabukuro M, Iwaki M. Increased oxidative stress in obesity and its impact on metabolic syndrome find the latest version: increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2017;11412:1752–61.

Google Scholar 

Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med. 2011;505:567–75.

Article  Google Scholar 

Chen YDI, Golay A, Swislocki ALM, Reaven GM. Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987;641:17–21.

Article  Google Scholar 

Baldeweg SE, Golay A, Natali A, Balkau B, Del Prato S, Coppack SW. Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. Eur J Clin Invest. 2000;301:45–52.

Article  Google Scholar 

Lönnqvist F, Thörne A, Nilsell K, Hoffstedt J, Arner P. A pathogenic role of visceral fat β3-adrenoceptors in obesity. J Clin Invest. 1995;953:1109–16.

Article  Google Scholar 

DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. the Claude Bernard lecture 2009. Diabetologia. 2010;537:1270–87.

Article  Google Scholar 

Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999;1032:253–9.

Article  Google Scholar 

Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97. https://doi.org/10.1038/nri2921.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Porte D, Kahn ESE. β-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes. 2001;50:9–12.

Article  Google Scholar 

Stumvoll M, Goldstein BJ, Haeften TW. Haeften_Pathogenesis of type 2 diabetes.pdf. Lancet. 2005;365:1333–46.

Article  CAS  PubMed  Google Scholar 

Kalra S. Diabesity. Recent Adv Endocrinol. 2013;63(4):5.

Google Scholar 

Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Endocrinol Metab. 2009;50:150–9.

Google Scholar 

Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: A review of current trends. Oman Med J. 2012;274:269–73.

Article  Google Scholar 

Makrilakis K. The role of dpp-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect. Int J Environ Res Public Health. 2019;16(15):2720.

Escalada FJ. Fisiología Del GLP-1 y Su papel En La fisiopatología de La diabetes mellitus Tipo 2. Med Clin [Barc]. 2014;143:2–7. https://doi.org/10.1016/S0025-7753[14]70101-0.

Article  Google Scholar 

Mentlein R. Dipeptidyl-peptidase IV [CD26]-role in the inactivation of regulatory peptides. Regul Pept. 1999;851:9–24.

Article  Google Scholar 

Nargis T, Chakrabarti P. Significance of circulatory DPP4 activity in metabolic diseases. IUBMB Life. 2018;702:112–9.

Article  Google Scholar 

Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res. 2004;36:747–54. [11–12].

Article  CAS  PubMed  Google Scholar 

Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;874:1409–39.

Article  Google Scholar 

Power O, Nongonierma AB, Jakeman P, Fitzgerald RJ. Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes. Proc Nutr Soc. 2014;731:34–46.

Article  Google Scholar 

Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol [Lausanne]. 2019;10:1–10.

Google Scholar 

Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, et al. Cause or Consequence Diabet State? Diabetes. 2007;56August:1951–9.

Google Scholar 

Creutzfeldt W. The incretin concept today. Diabetologia. 1979;162:75–85.

Article  Google Scholar 

Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 [non-insulin-dependent] diabetes. Diabetologia. 1986;291:46–52.

Article  Google Scholar 

Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998;4711:1663–70.

Article  Google Scholar 

Deacon CF. Physiology and Pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol. 2019;10.

Sesti G, Avogaro A, Belcastro S, Bonora BM, Croci M, Daniele G, et al. Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetol. 2019;566:605–17. https://doi.org/10.1007/s00592-018-1271-3.

Article  CAS  Google Scholar 

Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S, et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun [Internet]. 2013;4342:191–6. https://doi.org/10.1016/j.bbrc.2013.03.010.

Article  CAS  Google Scholar 

Tomovic K, Lazarevic J, Kocic G, Deljanin-Ilic M, Anderluh M, Smelcerovic A. Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection. Med Res Rev. 2019;391:404–22.

Article  Google Scholar 

Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes a meta-analysis. JAMA - J Am Med Assoc. 2016;3163:313–24.

Article  Google Scholar 

Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;1415:2047–58.

Article  Google Scholar 

Monami M, Vitale V, Ambrosio ML, Bartoli N, Toffanello G, Ragghianti B, et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, Pioglitazone, acarbose, and sulfonylureas: Meta-analysis of placebo-controlled trials. Adv Ther. 2012;299:736–46.

Article